Treatment of patients with type 2 diabetes with exenatide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goals

Table 2 Baseline demographics

	DURATION-4*				DURATION-2†			DURATION-3‡
	ExQW	Met	Sita	Pio	EQW	Sita	Pio	ExQW	IG
N	248	246	163	163	160	166	165	233	223
Sex (Male) (%)	56	63	58	60	56	52	48	52	55
Race (%)
American Indian or Alaska Native	<1	1	1	0	0	2	0	0	0
Asian	22	21	20	21	23	25	24	6	6
Black or African American	3	5	2	3	12	12	8	1	>1
Hispanic	7	9	8	9	31	30	27	12	9
Other	0	<1	0	0	1	1	2	0	0
White	68	65	69	68	33	30	39	82	85
Age (y)	54 ± 11	54 ± 11	52 ± 11	55 ± 11	52 ± 10	52 ± 11	53 ± 10	58 ± 10	58 ± 9
Duration of diabetes (y)	3 ± 3	3 ± 4	3 ± 4	3 ± 4	6 ± 5	5 ± 5	6 ± 6	8 ± 6	8 ± 6
Baseline weight (kg)	87 ± 19	86 ± 20	89 ± 19	86 ± 18	89 ± 20	87 ± 20	88 ± 21	91 ± 19	91 ± 16
Baseline BMI (kg/m ² )	31 ± 5	31 ± 5	32 ± 5	31 ± 5	32 ± 5	32 ± 5	33 ± 6	32 ± 5	32 ± 5
Baseline HbA1c (%)	8.5 ± 1.2	8.6 ± 1.2	8.5 ± 1.3	8.5 ± 1.2	8.6 ± 1.2	8.5 ± 1.2	8.5 ± 1.1	8.3 ± 1.1	8.3 ± 1.0
Baseline FBG (mmol/L)	9.9 ± 2.9	10.0 ± 3.4	9.7 ± 2.6	9.8 ± 3.0	9.2 ± 2.9	9.1 ± 2.5	9.1 ± 2.4	9.9 ± 2.5	9.7 ± 2.7
Baseline SBP (mm Hg)	129 ± 12	129 ± 15	130 ± 13	131 ± 15	126 ± 14	126 ± 14	127 ± 14	135 ± 17	133 ± 16
Baseline LDL (mmol/dL)	3.1 ± 1.1	2.9 ± 0.9	3.0 ± 0.9	3.1± 1.0	2.6 ± 0.8	2.8 ± 0.9	2.9 ± 1.0	2.7 ± 0.9	2.7 ± 0.9
Background therapy (n)
Metformin					160	166	165	164	157
Diet and Exercise	248	246	163	163
Metformin + Sulfonylurea								69	66

*†‡D iabetes Therapy U tilization: R esearching Changes in A 1C, Weight and Other Factors T hrough I ntervention with Exenatide O nce-W eekly-4, -2, -3 [23–25].
Values are shown as mean ± SD.
BMI , body mass index; DBP, diastolic blood pressure; ExQW, exenatide QW; HDL, high density lipoprotein cholesterol; IG, insulin glargine; Met, metformin; Pio, pioglitazone; Sita, sitagliptin.

ISSN: 1475-2840